RECRUITING

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To learn if an accelerated recovery program can shorten the length of hospital stay in patients having minimally invasive liver surgery.

Official Title

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

Quick Facts

Study Start:2023-10-05

Study Completion:2027-02-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05879159

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below) * No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results) * No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection * Ability to stay within 50 miles of medical center for immediate postop period * Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for patients \<18 years of age, children are excluded from this study * Ability to understand and the willingness to sign a written informed consent document * Non-English-speaking patients are eligible for participation	* Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy * Tumors not amenable to MIS or Robotic-assisted surgical resection * Evidence of Cirrhosis on imaging, clinically, or lab testing * Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period * Age below 18 years * Inability to consent for trial/protocol * Patients who are pregnant

Inclusion Criteria

Exclusion Criteria

* Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below)
* No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results)
* No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection
* Ability to stay within 50 miles of medical center for immediate postop period
* Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for patients \<18 years of age, children are excluded from this study
* Ability to understand and the willingness to sign a written informed consent document
* Non-English-speaking patients are eligible for participation

* Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy
* Tumors not amenable to MIS or Robotic-assisted surgical resection
* Evidence of Cirrhosis on imaging, clinically, or lab testing
* Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period
* Age below 18 years
* Inability to consent for trial/protocol
* Patients who are pregnant

Contacts and Locations

Study Contact

Hop Tran Cao, MD

CONTACT

(713) 745-4670

hstran@mdanderson.org

Principal Investigator

Hop Tran Cao, MD

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

M D Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Hop Tran Cao, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-05

Study Completion Date2027-02-01

Study Record Updates

Study Start Date2023-10-05

Study Completion Date2027-02-01

Terms related to this study

Additional Relevant MeSH Terms

Liver